Search alternatives:
no-show » no-how (Expand Search)
Showing 1 - 20 results of 451 for search 'multiple no-show patients', query time: 0.12s Refine Results
  1. 1

    Treatment of bone complications in multiple myeloma patients by V. V. Ptushkin

    Published 2022-11-01
    “…Results of controlled clinical trials showed that such a medications as clodronate, pamidronate and zoledronate considerably decrease the incidence of bone complications in patients with multiple myelomas. …”
    Get full text
    Article
  2. 2

    Surgical treatment of patients with multiple brain metastases by D. M. Belov, V. B. Karakhan, A. Kh. Bekyashev, E. V. Mitrofanov, E. V. Prozorenko, V. A. Aleshin, R. A. Sufianov, D. R. Nashletashvili

    Published 2024-06-01
    “…However, these disorders were moderate and did not reach the extent of dementia. The work done shows.Conclusion. Surgical removal of all metastases in patients with multiple brain metastases provides a prognosis similar to that of patients undergoing surgery for single metastasis. …”
    Get full text
    Article
  3. 3

    The condition of the cardiovascular system in patients with relapsing-remitting multiple sclerosis by O. A. Traktirskaya, T. V. Adasheva, A. N. Boyko, E. V. Popova

    Published 2019-03-01
    “…The main indicators of echocardiography were within normal values, no significant differences between the groups were found.Conclusion. The study showed that multiple sclerosis patients are at risk of developing cardiovascular diseases and require increased attention to prevent the development.…”
    Get full text
    Article
  4. 4

    Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma by K. A. Belousov, T. A. Mitina, Yu. Yu. Chuksina, A. K. Golenkov, E. V. Kataeva, E. V. Trifonova, Yu. B. Chernykh, L. L. Vysotskaya, S. G. Zakharov, E. F. Klinushkina, A. N. Mitin

    Published 2019-04-01
    “…Objective: to study the efficacy and safety of the antitumor RVP program (lenalidomide, bortezomib, prednisone) as a first-line therapy in patients with multiple myeloma (MM). Materials and methods. …”
    Get full text
    Article
  5. 5

    Bortezomib-induced peripheral neuropathy in patients with multiple myeloma: pain syndrome and psychopathological aspects by E. Z. Irugova, L. P. Mendeleeva, D. E. Vybornykh, M. V. Soloveva, S. Yu. Fedorova, M. V. Solovev

    Published 2025-03-01
    “…A study of patients’ psycho‑emotional states 100 days after auto‑HSCT showed a reduction in the frequency and severity of depressive states. …”
    Get full text
    Article
  6. 6
  7. 7

    Machine Learning for the Photonic Evaluation of Cranial and Extracranial Sites in Healthy Individuals and in Patients with Multiple Sclerosis by Antonio Currà, Riccardo Gasbarrone, Davide Gattabria, Nicola Luigi Bragazzi, Giuseppe Bonifazi, Silvia Serranti, Paolo Missori, Francesco Fattapposta, Carlotta Manfredi, Andrea Maffucci, Luca Puce, Lucio Marinelli, Carlo Trompetto

    Published 2025-07-01
    “…This study aims to characterize short-wave infrared (SWIR) reflectance spectra at cranial (at the scalp overlying the frontal cortex and the temporal bone window) and extracranial (biceps and triceps) sites in patients with multiple sclerosis (MS) and age-/sex-matched controls. …”
    Get full text
    Article
  8. 8

    The impact of 3-tesla breast MRI on the choice of the surgical plan in patients with multiple ipsilateral breast cancer by Bustan Mohamed Anwer, AlaaEldine AbdelHamid Mostafa, Eman ElBakoury, M. A. Elhussini, Hebatallah H. M. Hassan

    Published 2025-07-01
    “…Both modalities showed equivalent specificity (71.4%). In group B, MRI showed additional disease in 1/16 (6%). …”
    Get full text
    Article
  9. 9

    First-in-human experience of radiopharmaceutical therapy with [177Lu]Lu-DOTATATE in patients with advanced multiple myeloma by Wendy Delbart, Marie Vercruyssen, Rachele Danieli, Clémentine Marin, Zéna Wimana, Nathalie Meuleman, Patrick Flamen, Erwin Woff, Ioannis Karfis

    Published 2025-07-01
    “…One patient achieved sustained metabolic response and clinical stability over 12 months, while the second showed a complete metabolic response before experiencing biological progression. …”
    Get full text
    Article
  10. 10

    Comparative Effectiveness of Fumarates Versus Sphingosine-1-Phosphate Receptor Modulators in Black Patients with Multiple Sclerosis by Sophia Woodson, Edward J. Gettings, Chu-Yueh Guo, Sylvia Klineova, Jong-Mi Lee, Rebecca S. Romero, Aljoeson Walker, Nicholas Belviso, Sai L. Shankar, Jason P. Mendoza, Boyang Bian, James B. Lewin, Kinyee Fong

    Published 2025-06-01
    “…Kaplan–Meier analyses showed similar relapse-free proportions at 24 months (72.6% and 74.7% in fumerate and S1P populations, respectively; p = 0.152). …”
    Get full text
    Article
  11. 11

    Correlation Between Peripheral Blood Immune Cell Distribution and Disease Severity and Prognosis in Multiple Sclerosis Patients by Liu PJ, Yuan P, Liu SP

    Published 2025-07-01
    “…Disease severity and prognosis were assessed using the Expanded Disability Status Scale (EDSS) and Multiple Sclerosis Functional Composite (MSFC). Spearman correlation and multivariate linear regression (adjusted for age, gender, disease duration, and MS subtype) were employed to evaluate associations.Results: Of the MS patients studied, 10.4% (n=7) exhibited abnormal CSF pressure. …”
    Get full text
    Article
  12. 12
  13. 13

    Modern diagnostic potentials of studying structural and functional changes of the retina and the optic nerve in multiple sclerosis patients by A. Zh. Fursova, M. Yu. Zubkova, M. A. Vasilyeva, Yu. A. Gamza, N. A. Malkova, A. I. Prokaeva, F. K. Rabota

    Published 2023-12-01
    “…Purpose: to study significant functional and structural changes in the retina and the intraocular section of the optic nerve in multiple sclerosis (MS) patients and analyze how they are interrelated with electrophysiological changes in the visual analyzer.Materials and methods. …”
    Get full text
    Article
  14. 14
  15. 15

    Comparing cognitive impairment using MACFIMS in patients with multiple sclerosis and healthy controls: a systematic review and meta-analysis by Amirreza Nasirzadeh, Mohammad Mohammadi, Melika Arab Bafrani, Aynaz Mohammadi, Hossein Bakhtiari-Dovvombaygi

    Published 2024-11-01
    “…Methods This systematic review and meta-analysis aimed to evaluate cognitive function using the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) battery among pwMS patients and healthy controls (HCs). …”
    Get full text
    Article
  16. 16

    Characteristics and correlations of sleep disorders in patients with relapsing–remitting multiple sclerosis in China: a cross-sectional study by Rongrong Wang, Tengteng Zhang, Han Wang, Yao Ren, Runze Zhao, Gaopan Zhang, Guoxun Zhang, Xiongfei Zhao

    Published 2025-07-01
    “…BackgroundSleep disorders are a major but overlooked symptom in patients with multiple sclerosis (MS).ObjectivesThis article aims to investigate the characteristics of sleep disorders in patients with relapsing–remitting multiple sclerosis (RRMS) and to analyze the correlations between sleep disorders in RRMS and anxiety, depression, fatigue, and cognitive impairment.MethodsA total of 35 patients with RRMS and 35 controls were included, and both groups underwent assessments for sleep, anxiety, depression, fatigue, and cognitive function.ResultsThe RRMS group and the control group showed significant differences in Pittsburgh Sleep Quality Index (PSQI), Athens Insomnia Scale (AIS), Insomnia Severity Index (ISI), Hamilton Anxiety Scale (HAMA), Hamilton Depression Scale (HAMD), Modified Fatigue Impact Scale (MFIS), and Montreal Cognitive Assessment (MoCA). …”
    Get full text
    Article
  17. 17
  18. 18

    Management of patients with multiple primary сancer in the practice of a modern oncologist. Case report and literature review by D. A. Khlanta, G. P. Gens

    Published 2022-09-01
    “…The increase in the cancer incidence, as well as the need to make difficult decisions about further treatment strategy, enhance the relevance of studying multiple primary malignant neoplasms. This review discusses the current positions of medicine in relation to this category of malignant neoplasms, and presents a case report of a patient with this disaese. …”
    Get full text
    Article
  19. 19
  20. 20

    Personalized Treatment Response in Progressive MS: Can the Patient's Profile Influence the Outcome? by Francesca Bovis, Ludwig Kappos, Sophie Arnould, Goeril Karlsson, Maria Pia Sormani

    Published 2025-06-01
    “…Conclusions This analysis demonstrated the ability to define responders to a therapy based on their baseline profile and evaluate the treatment effect on multiple endpoints, showing that the benefit on different outcomes can vary across patients.…”
    Get full text
    Article